All Stories

  1. Headache with Neurological Deficits and CSF Lymphocytosis (HaNDL Syndrome)
  2. Global, regional, and national burden of headache disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
  3. Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
  4. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study...
  5. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
  6. Global, regional, and national burden of headache disorders, 1990–2021, with forecasts to 2050: A Global Burden of Disease study 2021
  7. The global, regional, and national burden attributable to low bone mineral density, 1990–2020: an analysis of a modifiable risk factor from the Global Burden of Disease Study 2021
  8. GBD 2023 Cardiovascular Disease Collaborators
  9. Global, regional, and national burden of epilepsy, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  10. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
  11. Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
  12. Epilepsy Arabic renaming to cerebroelectric disorder could minimize the stigma
  13. Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021
  14. International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine
  15. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine
  16. The burden of neurological conditions in north Africa and the Middle East, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
  17. Unveiling the retinal secrets of neuromyelitis optica spectrum disorder
  18. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  19. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a syst...
  20. Burden of disease scenarios for 204 countries
  21. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  22. Reliability, validity, and responsiveness of the Arabic version of HIT ‐6 questionnaire in patients with migraine indicated for preventive therapy: A multi‐center study
  23. Global Health Trends 1950–2021: Impact of COVID-19 on Mortality and Population Growth
  24. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  25. Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
  26. Validity and reliability of Arabic version of pediatric migraine disability assessment scale (Child Self-Report versus Parent Proxy-Report): a multi-center study
  27. The significance of miRNA-191-5P and miRNA-24-3P as novel biomarkers for multiple sclerosis: a case–control study
  28. Global Burden of Cardiovascular Diseases and Risks, 1990-2022
  29. Global, regional, and national burden of spinal cord injury, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  30. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
  31. The burden of metabolic risk factors in North Africa and the Middle East, 1990–2019: findings from the Global Burden of Disease Study
  32. Clinical Predictors of Transation to Secondary Progressive Multiple Sclerosis
  33. Neutrophil-to-Lymphocyte Ratio: a Marker of Neuro-inflammation in Multiple Sclerosis Patients: a Meta-analysis and Systematic Review
  34. Impact of nutrition counseling on anthropometry and dietary intake of multiple sclerosis patients at Kasr Alainy Multiple Sclerosis Unit, Cairo, Egypt 2019–2020: randomized controlled clinical trial
  35. Adolescent transport and unintentional injuries: a systematic analysis using the Global Burden of Disease Study 2019
  36. Board Walk
  37. Injury burden in individuals aged 50 years or older in the Eastern Mediterranean region, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019
  38. Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study
  39. Helicobacter pylori infection in migraine headache: A true association or an innocent bystander?
  40. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
  41. Neurological Manifestations in a Cohort of Egyptian Patients with COVID-19: A Prospective, Multicenter, Observational Study
  42. Impact of Ramadan fasting on disease activity in patients with multiple sclerosis: a multicenter study
  43. Changes in migraine characteristics over 30 days of Ramadan fasting: A prospective study
  44. The MuSC-19 study: The Egyptian cohort
  45. Mapping Anemia in Women: Global Trends and Inequality
  46. Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019
  47. Behavior and awareness of multiple sclerosis patients during COVID-19 pandemic in a tertiary center in Egypt
  48. MicroRNA-22 Level in Patients with Multiple Sclerosis and Its Relationship with Vitamin D and Vitamin D Receptor Levels
  49. Zinc deficiency correlates with severity of diabetic polyneuropathy
  50. Child Mortality Trends and Targets: GBD 2019 Findings
  51. Mapping inequalities in exclusive breastfeeding in low- and middle-income countries, 2000–2018
  52. Physical and Mental Fatigue in Subjects Recovered from COVID-19 Infection: A Case–Control Study
  53. Reliability and validity of Arabic version of the brief international cognitive assessment for multiple sclerosis: Egyptian dialect
  54. Bovine mastitis prevention and control in the post-antibiotic era
  55. lincR-Ccr2-5′AS and THRIL as potential biomarkers of multiple sclerosis
  56. The aquaporin4-IgG status and how it affects the clinical features and treatment response in NMOSD patients in Egypt
  57. Co-Occurrence of Guillain-Barre Syndrome and Multiple Sclerosis: A Rare Case Report
  58. Global mortality from dementia: Application of a new method and results from the Global Burden of Disease Study 2019
  59. The Burden of Dementia due to Down Syndrome, Parkinson’s Disease, Stroke, and Traumatic Brain Injury: A Systematic Analysis for the Global Burden of Disease Study 2019
  60. The potential role of 2D-speckle tracking echocardiography for detecting left ventricular systolic dysfunction in patients with Parkinson’s disease: a case control study
  61. Five insights from the Global Burden of Disease Study 2019
  62. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  63. FOXP3 rs3761548 gene variant and interleukin-35 serum levels as biomarkers in patients with multiple sclerosis
  64. Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era
  65. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  66. Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach
  67. Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization
  68. Glutamate and Nitric Oxide as biomarkers for disease activity in patients with multiple sclerosis
  69. Impact of insulin resistance and metabolic syndrome on disability in patients with multiple sclerosis
  70. Thalamic Involvement and its Impact on Disability and Cognition in Multiple Sclerosis: A Clinical and Diffusion Tensor Imaging Study
  71. Assessment of School-Aged Children of Mothers With Idiopathic Generalized Epilepsy
  72. Evaluating optic nerve diameter as a possible biomarker for disability in patients with multiple sclerosis
  73. Proprioception Errors in Patients with Cervical Spondylosis at Sagittal Plane
  74. Diffusivity Parameters as Markers for NAGM Involvement and Disease Progression in MS Patients: Diffusion Tensor Imaging Study
  75. Testing of Verbal Fluency in Egyptians
  76. Role of concentric needle Single Fiber Electromyography in detection of subclinical motor involvement in carpal tunnel syndrome
  77. Pediatric-onset multiple sclerosis in Egypt: a multi-center registry of 186 patients
  78. Objective pain assessment by electrical stimulation
  79. Clinical, diffusion tensor imaging, and cognitive biomarkers of seizure control in patients with juvenile myoclonic epilepsy
  80. Verbal fluency tests in Egyptians: Cultural and educational challenges
  81. P295 Effects of functional electric stimulation and task specific training on gait recovery in patients with stroke: Randomized controlled trial
  82. Characteristics and predictors of progression in an Egyptian multiple sclerosis cohort: a multicenter registry study
  83. Urinary 6-Sulphatoxymelatonin Levels and Sleep Disorders in Children With Migraine